Lonza Group AG

Lonza Group AG is one of the world’s largest Contract Development and Manufacturing Organizations (CDMOs), providing integrated solutions for the pharmaceutical, biotechnology, and healthcare industries. Founded in 1897 and headquartered in Basel, Switzerland, Lonza has built a global reputation for supporting the development and commercial manufacturing of biologics, cell and gene therapies, mammalian products, microbial products, antibody-drug conjugates (ADCs), and small molecule pharmaceuticals.

The company partners with leading pharmaceutical companies and emerging biotechnology firms, offering services across the entire drug development lifecycle—from early-stage process development and clinical manufacturing to large-scale commercial production. Lonza is particularly recognized for its expertise in biologics manufacturing, cell therapy, viral vectors, microbial fermentation, and advanced bioprocessing technologies.

Operating more than 30 manufacturing and research facilities across Europe, North America, and Asia, Lonza maintains strict compliance with international regulatory standards including US FDA, EMA, MHRA, Swissmedic, and PMDA requirements. The company continuously invests in automation, digital manufacturing, sustainability, and next-generation production technologies to meet the growing demand for advanced therapies.

Through scientific excellence, regulatory expertise, and long-term customer partnerships, Lonza has become one of the pharmaceutical industry’s most trusted CDMO providers, helping accelerate the delivery of innovative medicines to patients worldwide.